Breadcrumb Home Business Activities Lundbeckfonden BioCapital Lundbeckfonden BioCapital Portfolio Celladon Celladon Was in phase II/III trial with a SERCa2a gene therapy to help heart failure patients hearts to beat without increasing their oxygen consumption. Lundbeckfonden BioCapital Invested 2010 IPO in 2013 – CLDN (Nasdaq) Location La Jolla, California, USA